Biotech Co.* |
Pharma Co. |
Product | Terms/Details (Date) |
| | |||
Advancis |
Stada Arzneimittel AG (Germany) |
Stada will supply Amoxicillin Pulsys products for Advancis |
Stada subsidiary Clonmel Healthcare Ltd. will provide commercial supplies of the product, which is in Phase III trials for treating infections (4/19) |
| |||
Affymetrix |
CapitalBio Corp. (China) |
Deal to develop an advanced GeneChip-compatible personal scanner and a service provider program |
CapitalBio will offer the full line of Affymetrix GeneChip products under the deal; they intend to collaborate in other areas, as well (4/26) |
| |||
Alnylam |
Dowpharma (unit of The Dow Chemical Co.) |
Deal for the manufacture and supply of Alnylam candidate RNAi therapeutics |
Dowpharma will manufacture siRNAs for use in clinical trials in age-related macular degeneration and respiratory syncytial virus infection (3/29) |
| |||
Ambion Inc.* |
Wyeth |
Deal to continue alliance for development and supply of cGMP-grade RNA that will be incorporated in Wyeth's vaccine program |
Ambion division Ambion Diagnostics will manufacture RNA transcripts and supply the material for Phase I/II trials (3/8) |
| |||
Antisoma plc |
Raylo Chemicals (Canada) |
Deal for the manufacture of Antisoma's AS1411 (formerly AGRO100) |
The product is an anticancer aptamer; terms of the deal were not disclosed (3/14) |
| |||
Arexis AB* |
CMC Biopharmceuticals (Denmark) |
Deal for the production of Arexis' recombinant human BSSL product for upcoming clinical trials |
The bile salt-stimulated lipase will be tested for cystic fibrosis and preterm infants; terms of the deal were not disclosed (3/7) |
| |||
Cellegy |
PT Kalbe Farma (Indonesia) |
PT Kalbe got rights to distribute Tostrex (testosterone gel) in parts of the Far East |
PT Kalbe got exclusive distribution rights in 11 countries, including Indonesia and Thailand; terms of the deal were not disclosed (3/9) |
| |||
Cytomedix Inc. |
KOL Bio-Medical Instruments Inc. |
KOL will represent the company in certain East Coast areas |
The six-month deal relates to Cytomedix's AutoloGel therapy; the commission-fee deal could be renewed (3/14) |
| |||
Evolutec |
Cambrex Bio Science Baltimore Inc. |
Cambrex will manufacture Evolutec's rEV131 for Phase III trials and marketing |
The product is in Phase II trials in allergic rhinitis and post- operative treatment fol- lowing cataract surgery; terms were not disclosed (2/28) |
| |||
GeneExcel |
ITX International Holdings Inc. |
ITX licensed liposome drug delivery technology for entrance into Japan markets |
ITX invested $700,000 in GeneExcel's Series A financing; further terms were not disclosed (3/15) |
| |||
Gilead |
Aspen Pharmacare (South Africa) |
Aspen will manufacture and distribute Gilead's HIV products Truvada and Viread in Africa |
The nonexclusive deal includes the 95 resource-limited countries in Gilead's global access program; Aspen also will be responsible for regulatory approvals (4/25) |
| |||
Large Scale |
EMD Biosciences Inc. (unit of Merck KGaA) |
LSBC will manufacture and supply one of its protein products for distribution by EMD |
Terms of the multiyear agreement were not disclosed (4/28) |
| |||
OpGen Inc.* |
M&S |
M&S got exclusive distribution rights to OpGen products in Japan |
M&S will provide researchers access to Optical Mapping, OpGen's whole-genome analysis system, under undisclosed terms (4/28) |
| |||
Proteome |
Agilent Technologies Inc. |
Collaboration to develop an integrated solution for the analysis of glycoproteins |
Proteome will make its GlycomIQ software platform compatible with Agilent's ion trap mass spectrometers (4/18) |
| |||
Salix |
Altana Pharma U.S. Inc. |
Altana will co-promote Salix's Xifaxan (rifaximin) |
Altana will promote the product for travelers' diarrhea to the primary care physician market; terms were not disclosed (3/3) |
| |||
Spectrum |
Cura Pharmaceuticals Co. Inc. |
Deal under which Cura would market Spectrum's carboplatin injection product |
Spectrum expects approval of the generic cancer product by mid-2005; terms of the deal were not disclosed (4/14) |
| |||
WITA GmbH* |
SC Biosciences Corp. (Japan) |
SCBC will distribute WITA's proteomics technologies in Japan |
Terms of the deal were not disclosed (4/27) |
| | |||
Notes: | |||
| |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. | |||
